Targeting the c-kit receptor in the treatment of acute myelogenous leukemia

Current Hematologic Malignancy Reports

Volumn 1, Issue 2, 2006, Pages 101-107

  Advani, Anjali S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; IMATINIB; SEMAXANIB; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; GENE MUTATION; HEMATOPOIESIS; HUMAN; PROTEIN EXPRESSION; REVIEW; STEM CELL;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 33750312819     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-006-0020-9     Document Type: Review

References (55)

1. Miller K, Daoust P: Clinical manifestations of acute myeloid leukemia. In Hematology: Basic Principles and Practice, edn 3. Edited by Hoffman R, Benz EJ Jr, Shattil SJ, et al. New York: Churchill Livingstone, 2000: 2017-2018.
2. Hans CP, Finn WG, Singleton TP, et al.: Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia. Am J Clin Pathol 2002, 117:301-305.
3. Del Poeta G, Venditti A, Maurillo L, et al.: The amount of c-kit receptor tyrosine kinase predicts outcome in acute myelogenous leukemia. Blood (ASH Annual Meeting Abstracts) 2001, 98:716a (Abstract 2992).
4. Tajima F, Kawatani T, Ishiga K, et al.: Serum soluble c-kit receptor and expression of c-kit protein and mRNA in acute myeloid leukemia. Eur J Haematol 1998, 60:289-296.
5. Yarden Y, Kuang WI, Yang-Feng T, et al.: Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. Embo J 1987, 6:3341-3351.
6. Zsebo KM, Williams DA, Geissler EN, et al.: Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990, 63:213-224.
7. Lev S, Givol D, Yarden Y: A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. Embo J 1991, 10:647-654.
8. Piao X, Curtis JE, Minkin S, et al.: Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia. Blood 1994, 83:476-481.
9. Koch CA, Anderson D, Moran MF, et al.: SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 1991, 252:668-674.
10. Kindler T, Breitenbuecher F, Marx A, et al.: Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 2003, 101:2960-2962.
11. Linnekin D: Early signaling pathways activated by c-Kit in hematopoietic progenitor cells. Int J Biochem Cell Biol 1999, 31:1053-1074.
12. Ikeda H, Kanakura Y, Furitsu T, et al.: Changes in phenotype and proliferative potential of human acute myeloblastic leukemia cells in culture with stem cell factor. Exp Hematol 1993, 21:1686-1694.
13. Domen J, Weissman IL: Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, KitI/c-Kit signaling the other. J Exp Med 2000, 192:1707-1718.
14. Pietsch T, Kyas U, Steffens U, et al.: Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1992, 80:1199-1206.
15. Ikeda H, Kanakura Y, Tamaki T, et al.: Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991, 78:2962-2968.
16. Sperling C, Schwartz S, Buchner T, et al.: Expression of the stem cell factor c-kit (CD117) in acute leukemias. Haematologica 1997, 82:617-621.
17. Schwartz S, Heinecke A, Zimmerman M, et al.: Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma 1999, 34:85-94.
18. Kawakita M, Yonemura Y, Miyake H, et al.: Soluble c-kit molecule in serum from healthy individuals and patients with haemopoietic disorders. Br J Haematol 1995, 91:23-29.
19. Wang C, Curtis JE, Geissler EN, et al.: The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. Leukemia 1989, 3:699-702.
20. Zheng R, Klang K, Gorin N, et al.: Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. Leuk Res 2004, 28:121-126. Discusses the importance of c-kit expression in AML.
21. Hassan H, Zander A: Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol 1996, 95:257-262.
22. Bendall L, Makrynikola V, Hutchinson A, et al.: Stem cell factor enhances the adhesion of AML cells to fibronectin and augments fibronectin-mediated anti-apoptotic and proliferative signals. Leukemia 1998, 12:1375-1382.
23. Caceres-Cortes J, Alvarado-Moreno J, Waga K, et al.: Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Res 2001, 61:6281-6289.
24. Buhring H, Herbst R, Kostka G, et al.: Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia. Cancer Res 1993, 53:4424-4431.
25. Ashman L, Roberts M, Gadd S, et al.: Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. Leuk Res 1988, 12:923-928.
26. Lerner NB, Nocka KH, Cole SR, et al.: Monoclonal antibody YB5.B8 identifies the human c-kit protein product. Blood 1991, 77:1876-1883.
27. Sincock P, Ashman L: Expression of c-kit and functional drug efflux are correlated in de novo acute myeloid leukaemia. Leukemia 1997, 11:1850-1857.
28. Del Poeta G, Venditti A, Del Principe MI, et al.: Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003, 101:2125-2131. Discusses the importance of apoptotic markers and prognosis in AML.
29. Carson WE, Haldar S, Baiocchi RA, et al.: The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci U S A 1994, 91:7553-7557.
30. Bradstock K, Matthews J, Benson E, et al.: Prognostic value of immunophenotyping in acute myeloid leukemia. Blood 1994, 84:1220-1225.
31. Tsao A, Kantarjian H, Thomas D, et al.: C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res 2004, 28:373-378.
32. Saber W, Abou-Jawde R, Hsi E, et al.: CD117 expression is a poor prognostic factor for progression free survival and freedom from progression in patients with newly diagnosed acute myelogenous leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:921a (Abstract 3292).
33. Scappini B, Onida F, Kantarjian H, et al.: Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res 2001, 7:3884-3893.
34. Ning Z, Li J, Arceci R: Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells. Leak lymphoma 2001, 41:513-522.
35. Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002, 20:1692-1703. A review of the biology and clinical applications of the new c-kit inhibitors.
36. Ning ZQ, Li J, Arceci RJ: Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-kit-mediated cytokine-independent survival and proliferation in leukemia cells. Blood 2001, 97:3559-3567.
37. Cilliland D: Molecular genetics of human leukemias: new insights into therapy [review]. Semin Hematol 2002, 39:6-11.
38. Lorenzo F, Nishii K, Monma F, et al.: Distinct characteristics of t(8;21) acute myeloid leukemia with active kit mutation [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:922a (Abstract 3297).
39. Gari M, Goodeve A, Wilson G, et al.: c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukemia. Br J Haematol 1999, 105:894-900.
40. Longley B, Reguera M, Ma Y: Classes of c-kit activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leak Res 2001, 25:571-576.
41. Lowenberg B, van Putten W, Theobald M, et al.: Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003, 349:743-752.
42. Buchdunger E, Cioffi C, Law N, et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295:139-145.
43. Druker B, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
44. Cortes J, Giles F, O'Brien S, et al.: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003, 97:2760-2766.
45. Kindler T, Breitenbuecher F, Marx A, et al.: Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004, 103:3644-3654. Discusses the biology and clinical results of using imatinib in patients with AML.
46. Caruana G, Cambareri A, Ashman L: Isoforms of c-kit differ in activation of signaling pathways and transformation of NIH3T3 fibroblasts. Oncogene 1999, 18:5573-5581.
47. Fang G, Kim C, Perkins C, et al.: CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive leukemia cells to apoptosis due to antileukemic drugs. Blood 2000, 96:2246-2253.
48. Heidel F, Cortes J, Ruecker F, et al.: Results of a multicenter phase II trial for older patients with c-kit positive acute myeloid leukemia and high-risk myelodysplastic syndrome using low-dose Ara-C and imatinib [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:527a (Abstract 1853).
49. Spiekermann K, Farber F, Voswinckel R, et al.: The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol 2002, 30:767-773.
50. Smolich BD, Yuen HA, West KA, et al.: The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemic blasts. Blood 2001, 97:1413-1421.
51. Giles F, Stopeck A, Silverman L, et al.: SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003, 102:795-801.
52. Fiedler W, Mesters R, Tinnefeld H, et al.: A phase II clinical study of SU5417 in patients with refractory acute myeloid leukemia. Blood 2003, 102:2763-2767.
53. Gleixner KV, Mayerhofer M, Aichberger KJ, et al.: PKC412 inhibits in vitro growth of neoplastic mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107 and imatinib, and evaluations of drug interactions [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:983a (Abstract 3523).
54. Schittenhelm MM, Shiraga S, Schroeder A, et al.: Dasatinib (BMS-354825), a multi-targeted kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane and activation loop mutant KIT isoforms associated with human malignancies [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:938a (Abstract 3358).
55. Shankar DB, Chang JC, Parcells B, et al.: The multi-targeted receptor tyrosine kinase inhibitor, ABT-869, induces apoptosis of AML cells both in vitro and in vivo. Blood (ASH Annual Meeting Abstracts) 2005, 106:183a (Abstract 616).